ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve

 
• By Reed Miller

In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.

Core Valve In Situ
Medtronic's CoreValve transcatheter aortic valve in situ • Source: SOURCE: Medtronic PLC

Two-year results of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial show that transcatheter aortic valve replacement with Medtronic PLC's CoreValve or CoreValve Evolut R is noninferior to surgical valve replacement in patients with aortic stenosis at intermediate risk of complications during surgery.

"We made our two-year non-inferiority endpoint with very strong statistics," SURTAVI's lead investigator, surgeon Michael Reardon of Houston Methodist DeBakey Heart & Vascular Center, told Medtech Insight

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

More from Device Area